EXCOA-CVT Long-Term
(2026)Objective
To investigate the long-term (24-month) effect of extended (12 months) vs short (3-6 months) post-acute oral anticoagulation after cerebral venous thrombosis.
Study Summary
• Primary symptomatic and confirmed fatal/nonfatal VTE: 4.4% vs 7.7%, HR 0.58 (0.20-1.70).
• Bleeding: 4% vs 5% (NS); mortality 2.6% vs 0.0% (NS).
• Composite recurrent VTE + major bleeding: 6.2% vs 9.1% (NS).
• Cluster RCT terminated prematurely; prospective cohort showed similar results.
• Bleeding: 4% vs 5% (NS); mortality 2.6% vs 0.0% (NS).
• Composite recurrent VTE + major bleeding: 6.2% vs 9.1% (NS).
• Cluster RCT terminated prematurely; prospective cohort showed similar results.
Intervention
Long-term oral anticoagulation 12 months vs short-term OAC 3-6 months after CVT
Inclusion Criteria
Europe, Russia, India, Mexico, Brazil. Radiologically confirmed CVT within 30 days; stable to initiate post-acute anticoagulation.
Study Design
Arms: Long-term OAC (12 mo) vs Short-term OAC (3-6 mo)
Patients per Arm: RCT: Long-term n=221 vs Short-term n=227; Prospective cohort: 295 vs 514
Outcome
• Primary symptomatic VTE (fatal/nonfatal): 4.4% vs 7.7%, HR 0.58 (0.20-1.70).
• Bleeding: 4% vs 5% (NS).
• Mortality: 2.6% vs 0.0% (NS).
• Composite VTE + major bleeding: 6.2% vs 9.1% (NS).
• Bleeding: 4% vs 5% (NS).
• Mortality: 2.6% vs 0.0% (NS).
• Composite VTE + major bleeding: 6.2% vs 9.1% (NS).